<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03462173</url>
  </required_header>
  <id_info>
    <org_study_id>PCD-DDAG181PA-13-001</org_study_id>
    <nct_id>NCT03462173</nct_id>
  </id_info>
  <brief_title>The Safety, Tolerability and Pharmacokinetic Study of Yimitasvir in Healthy Adults Subjects</brief_title>
  <official_title>A Phase I, Randomized，Double-blind, Placebo-controlled, Single Ascending Dose, Single-center Study to Assess the Safety, Tolerability and Pharmacokinetic of Yimitasvir in Healthy Adults Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunshine Lake Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunshine Lake Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Safety, Tolerability and Pharmacokinetic Study of Chronic Hepatitis C Treatment Drug
      Yimitasvir in Healthy Adults Subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a Randomized，Double-blind, Placebo-controlled, Single Ascending Dose, Single-center
      Study to Assess the Safety, Tolerability and Pharmacokinetic of Yimitasvir in Healthy Adults
      Subjects

      A total of 56 healthy subjects were divided into 7 groups, with each group consisting of 8
      subjects. Six of the subjects received the investigational drug, and two received placebo.
      All of the subjects received a single dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 3, 2014</start_date>
  <completion_date type="Actual">January 22, 2016</completion_date>
  <primary_completion_date type="Actual">January 30, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Baseline to day 10</time_frame>
    <description>To assess the safety and tolerability after a single dose of DAG181</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Prior to dosing (0 h) and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 h after dosing</time_frame>
    <description>Maximum observed plasma concentration of DAG181</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>Prior to dosing (0 h) and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 h after dosing</time_frame>
    <description>Time of the maximum observed plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>Prior to dosing (0 h) and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 h after dosing</time_frame>
    <description>Area under the plasma concentration-time curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2</measure>
    <time_frame>Prior to dosing (0 h) and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 h after dosing</time_frame>
    <description>Terminal elimination half-life</description>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Chronic Hepatitis c</condition>
  <arm_group>
    <arm_group_label>30 mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects, receiving a single dose of 30 mg yimitasvir(N=6) or placebo(N=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects, receiving a single dose of 100 mg yimitasvir (N=6) or placebo(N=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects, receiving a single dose of 200 mg yimitasvir (N=6) or placebo(N=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>400 mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects, receiving a single dose of 400 mg yimitasvir (N=6) or placebo(N=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>600 mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects, receiving a single dose of 600 mg yimitasvir (N=6) or placebo(N=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>800 mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects, receiving a single dose of 800 mg yimitasvir (N=6) or placebo(N=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1000 mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects, receiving a single dose of 1000 mg yimitasvir (N=6) or placebo(N=2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>yimitasvir</intervention_name>
    <description>Capsule administered orally once daily</description>
    <arm_group_label>30 mg single dose</arm_group_label>
    <arm_group_label>100 mg single dose</arm_group_label>
    <arm_group_label>200 mg single dose</arm_group_label>
    <arm_group_label>400 mg single dose</arm_group_label>
    <arm_group_label>600 mg single dose</arm_group_label>
    <arm_group_label>800 mg single dose</arm_group_label>
    <arm_group_label>1000 mg single dose</arm_group_label>
    <other_name>DAG181</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Matching Placebo Capsule</description>
    <arm_group_label>30 mg single dose</arm_group_label>
    <arm_group_label>100 mg single dose</arm_group_label>
    <arm_group_label>200 mg single dose</arm_group_label>
    <arm_group_label>400 mg single dose</arm_group_label>
    <arm_group_label>600 mg single dose</arm_group_label>
    <arm_group_label>800 mg single dose</arm_group_label>
    <arm_group_label>1000 mg single dose</arm_group_label>
    <other_name>DAG181 placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, overall healthy subjects;

          -  Between 18 and 45 years of age, inclusive, similar ages;

          -  Body weight should be≥50 kg; Body Mass Index (BMI) is between 19 and 25 kg/m2,
             inclusive, similar body weights;

          -  Able to comprehend and sign the ICF voluntarily prior to initiate the study;

          -  Able to communicate well with the investigator and complete the study according to the
             protocol.

        Exclusion Criteria:

          -  Pregnant or nursing female, or plan for pregnancy within 6 months;

          -  Female with positive urine pregnancy test results;

          -  Positive test results for HBsAg, anti-HCV Ab, anti-HIV Ab or syphilis;

          -  Have taken any drug inhibiting gastric acid secretion within 1 month prior to study
             drug administration, such as: H2 receptor antagonists (eg: Cimetidine, Ranitidine,
             Famotidine, Nizatidine and Roxatidine); Proton pump inhibitors (eg: Omeprazole,
             Lansoprazole, Rabeprazole, Pantoprazole and Esomeprazole); cholinoceptor blocking
             drugs (eg: Atropine and Pirenzepine);

          -  History of immune system disease (such as thymus disease);

          -  Have undergone major surgery within 6 months before enrollment;

          -  History of tumor;

          -  Drink frequently within 6 months prior to study drug administration, namely alcohol
             consumption are more than 20 grams per day;

          -  Smokers, who smoke more than 1 cigarettes/day within 3 months before the study;

          -  Participated in any clinical trial within 3 months prior to the study;

          -  Cannot be tolerant to oral drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yimin Cui, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2018</study_first_submitted>
  <study_first_submitted_qc>March 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2018</study_first_posted>
  <last_update_submitted>March 8, 2018</last_update_submitted>
  <last_update_submitted_qc>March 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

